EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Darolutamide in Black/African–American Patients from the Phase III ARAMIS Study

Neal D Shore iD, Felipe Cruz, Luke Nordquist, Laurence Belkoff, William J Aronson, Bhupendra Tolia, Arnold Cinman, Roohollah Sharifi, Jorge Ortiz, Jacqueline Parkin, Shankar Srinivasan, Toni Sarapohja und 1 weitere

Future Oncology · 2022

DOI: 10.2217/fon-2022-0943 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Future Oncology, 2022. Verfasst von Neal D Shore und 12 weiteren Autor:innen. Beteiligte Einrichtung: Carolina Urologic Research Center/Genesis Care, Myrtle Beach, SC 29577, USA. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists, Black or African American, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer HealthCare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Darolutamide significantly improved metastasis-free survival (MFS) and overall survival (OS) versus placebo in the phase III ARAMIS study. We evaluated outcomes in Black/African-American patients in ARAMIS. Materials & methods: Patients with nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide (n = 955) or placebo (n = 554) plus androgen-deprivation therapy. The primary end point was MFS. Secondary end points included OS and safety.

Results

In 52 (3.4%) Black/African-American patients, darolutamide improved MFS (median: not reached vs 12.4 months) and OS (3-year survival rates: 100 vs 71%) versus placebo. The safety profile of darolutamide in Black/African-American patients was consistent with that of all ARAMIS patients.

Conclusion

In Black/African-American patients, darolutamide improved MFS and OS and was well tolerated, consistent with the overall ARAMIS population. In patients with prostate cancer that has stopped responding to androgen-deprivation therapy, or ‘ADT,’ and has not spread to other parts of the body (known as nonmetastatic castration-resistant prostate cancer, or ‘nmCRPC’), darolutamide is an oral treatment option. Darolutamide added to ADT was tested in patients with nmCRPC in a large international study called ARAMIS and was found to prolong the time that patients were free from their cancer spreading compared with patients who received ADT alone. This report provides information on the effect of darolutamide in the 52 Black/African–American patients who took part in ARAMIS. In these patients, darolutamide showed similar effects on lowering the risk of their cancer spreading and was well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen Receptor AntagonistsBlack or African AmericanProstatic Neoplasms, Castration-ResistantHumansMaleAndrogen AntagonistsPyrazoles

Stichwörter der Autor:innen

African–Americanandrogen receptor antagonistcastration-resistant prostatic neoplasmsdarolutamidesurvival analyses

Substanzen

Androgen AntagonistsAndrogen Receptor AntagonistsdarolutamidePyrazoles

Autor:innen und Institutionen

  • Carolina Urologic Research Center/Genesis Care, Myrtle Beach, SC 29577, USA.
  • Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo, 03102-002, Brazil.
  • Urology Cancer Center, Omaha, NE 68130, USA.
  • Urologic Consultants of Southeastern PA, Bala Cynwyd, PA 19004, USA.
  • University of California, Los Angeles, CA 90095, USA.
  • New York Health, Eastchester Center for Cancer Care, Bronx, NY 10469, USA.

ORCID-Profile: Neal D Shore

Förderung

  • Bayer HealthCare

Zitieren

APA

Shore, N. D., Cruz, F., Nordquist, L., Belkoff, L., Aronson, W. J., Tolia, B., Cinman, A., Sharifi, R., Ortiz, J., Parkin, J., Srinivasan, S., Sarapohja, T., & Smith, M. R. (2022). Efficacy and Safety of Darolutamide in Black/African–American Patients from the Phase III ARAMIS Study. Future Oncology. https://doi.org/10.2217/fon-2022-0943

Vancouver

Shore ND, Cruz F, Nordquist L, Belkoff L, Aronson WJ, Tolia B, et al. Efficacy and Safety of Darolutamide in Black/African–American Patients from the Phase III ARAMIS Study. Future Oncology. 2022. doi:10.2217/fon-2022-0943

BibTeX
@article{Shore2022,
  author = {Shore, Neal D and Cruz, Felipe and Nordquist, Luke and Belkoff, Laurence and Aronson, William J and Tolia, Bhupendra and Cinman, Arnold and Sharifi, Roohollah and Ortiz, Jorge and Parkin, Jacqueline and Srinivasan, Shankar and Sarapohja, Toni and Smith, Matthew R},
  title = {Efficacy and Safety of Darolutamide in Black/African–American Patients from the Phase III ARAMIS Study},
  journal = {Future Oncology},
  year = {2022},
  doi = {10.2217/fon-2022-0943}
}
Kostenlos starten →